• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Randy Osborne

Articles by Randy Osborne

Restructuring Popular Strategy As Market, Investors Apply Pressure

Aug. 26, 2002
By Randy Osborne
When flailing giant Elan Corp. plc made known its plan to restructure at the end of last month, tremors were felt worldwide. The Securities and Exchange Commission had raised questions about off-balance-sheet accounting procedures related to Elan's joint ventures, of which the company has no less than 55, and there had been shareholder lawsuits along with the more ordinary kind of problems, such as the suspension of clinical dosing of the Alzheimer's drug partnered with Wyeth-Ayerst Laboratories. (BioWorld Financial Watch)
Read More

NeoTherapeutics Restructures To Focus On Cancer, Out-Licensing

Aug. 23, 2002
By Randy Osborne

SEC, Accounting Boards To Put Squeeze On Reporting Practices

Aug. 19, 2002
By Randy Osborne
In the scandal-ridden business world - where allegations of accounting manipulations and insider trading have been flying like chopped food out of an untopped Martha Stewart food processor - biotechnology, like every other sector, has been spattered. (BioWorld Financial Watch)
Read More

Keryx Reduces Staff, Salaries, Plans Kidney Drug Phase III

Aug. 15, 2002
By Randy Osborne

CollaGenex Testing Periostat In Phase III Against Rosacea

Aug. 14, 2002
By Randy Osborne

Corixa Adds Resources With $45M Stock, Warrant Sale

Aug. 13, 2002
By Randy Osborne
If the FDA's delay of approval for Corixa Corp.'s lead cancer product, Bexxar (tositumomab, iodine-131), is doing harm regarding investors, you wouldn't know it from the company's news Monday that it entered a purchase agreement to raise about $45 million in a private placement. (BioWorld Today)
Read More

Enzo Patent Decision Sends Important Case Back To Trial

Aug. 5, 2002
By Randy Osborne

Despite Humicade Phase III Bomb, Anti-TNFs Strong Against Crohn's

Aug. 5, 2002
By Randy Osborne
A drug's blow-up in Phase III trials is hardly easy to take in stride, but Biogen Inc. came out of its failure last week seeming not much the worse for wear in the eyes of Wall Street, even if nobody at the company was popping champagne corks. (BioWorld Financial Watch)
Read More

ViroPharma, Aventis Ending Deal For Picovir Development

Aug. 2, 2002
By Randy Osborne
With news that its deal with Aventis Pharmaceuticals Inc. to develop Picovir (pleconaril) is being terminated by mutual agreement, ViroPharma Inc.'s stock took another trouncing - and the company disclosed plans to restructure, cutting its work force by 63 percent. (BioWorld Today)
Read More

Versicor, Biosearch Merging In Stock Swap Valued At $261M

Aug. 1, 2002
By Randy Osborne
With the antibiotic dalbavancin in Phase II trials, Versicor Inc. said it has agreed to buy collaborator Biosearch Italia SpA - from which it gained the rights to the drug - for $260.7 million in a stock swap expected to close early next year. (BioWorld Today)
Read More
Previous 1 2 … 440 441 442 443 444 445 446 447 448 … 455 456 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 25, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe